Your browser doesn't support javascript.
Induction of Hepatitis E Virus Anti-ORF3 Antibodies from Systemic Administration of a Muscle-Specific Adeno-Associated Virus (AAV) Vector.
Maurer, Lars; El Andari, Jihad; Rapti, Kleopatra; Spreyer, Laura; Steinmann, Eike; Grimm, Dirk; Dao Thi, Viet Loan.
  • Maurer L; Schaller Research Group, Department of Infectious Diseases, Virology, University Hospital Heidelberg, Center for Integrative Infectious Diseases Research (CIID), 61920 Heidelberg, Germany.
  • El Andari J; Department of Infectious Diseases, Virology, University Hospital Heidelberg, Cluster of Excellence CellNetworks, BioQuant, Center for Integrative Infectious Diseases Research (CIID), 69120 Heidelberg, Germany.
  • Rapti K; Department of Infectious Diseases, Virology, University Hospital Heidelberg, Cluster of Excellence CellNetworks, BioQuant, Center for Integrative Infectious Diseases Research (CIID), 69120 Heidelberg, Germany.
  • Spreyer L; Department of Infectious Diseases, Virology, University Hospital Heidelberg, Cluster of Excellence CellNetworks, BioQuant, Center for Integrative Infectious Diseases Research (CIID), 69120 Heidelberg, Germany.
  • Steinmann E; Schaller Research Group, Department of Infectious Diseases, Virology, University Hospital Heidelberg, Center for Integrative Infectious Diseases Research (CIID), 61920 Heidelberg, Germany.
  • Grimm D; Department of Molecular and Medical Virology, Ruhr-University Bochum, 44801 Bochum, Germany.
  • Dao Thi VL; German Center for Infection Research (DZIF), External Partner Site Bochum, 44801 Bochum, Germany.
Viruses ; 14(2)2022 01 27.
Article in English | MEDLINE | ID: covidwho-1667342
ABSTRACT
The hepatitis E virus (HEV) is a major global health problem, leading to large outbreaks in the developing world and chronic infections in the developed world. HEV is a non-enveloped virus, which circulates in the blood in a quasi-enveloped form. The quasi-envelope protects HEV particles from neutralising anti-capsid antibodies in the serum; however, most vaccine approaches are designed to induce an immune response against the HEV capsid. In this study, we explored systemic in vivo administration of a novel synthetic and myotropic Adeno-associated virus vector (AAVMYO3) to express the small HEV phosphoprotein ORF3 (found on quasi-enveloped HEV) in the musculature of mice, resulting in the robust and dose-dependent formation of anti-ORF3 antibodies. Neutralisation assays using the serum of ORF3 AAV-transduced mice showed a modest inhibitory effect on the infection of quasi-enveloped HEV in vivo, comparable to previously characterised anti-ORF3 antibodies used as a control. The novel AAVMYO3 capsid used in this study can serve as a versatile platform for the continued development of vector-based vaccines against HEV and other infectious agents, which could complement traditional vaccines akin to the current positive experience with SARS-CoV-2.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Proteins / Hepatitis Antibodies / Hepatitis E virus / Dependovirus / Genetic Vectors / Muscles Topics: Vaccines Limits: Animals Language: English Year: 2022 Document Type: Article Affiliation country: V14020266

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Proteins / Hepatitis Antibodies / Hepatitis E virus / Dependovirus / Genetic Vectors / Muscles Topics: Vaccines Limits: Animals Language: English Year: 2022 Document Type: Article Affiliation country: V14020266